Feasibility of ICG labeling of axillary sentinel lymph nodes following neoadjuvant chemotherapy for breast cancer

Feasibility of ICG labeling of axillary sentinel lymph nodes following neoadjuvant chemotherapy for breast cancer - NeoICGBreast

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040580

Enrollment

100

Registered

2026-06-11

Start date

2025-01-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50.9

Interventions

Group 1: prospective, single-center, single-arm feasibility study (Recording of the number of detected sentinel lymph nodes (SLNs) intraoperatively/ histologically after neoadjuvant chemotherapy (NACT

comparison of the number of ICG-labeled SLNs removed from the prospective cohort with the number of SLNs removed after technetium labeling (retrospective data collection 2022–2024)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: invasive breast cancer neoadjuvant chemotherapy indication for SLNB/TAD written consent

Exclusion criteria

Exclusion criteria: Iodine allergy Hyperthyroidism/autonomous thyroid adenomas Pregnancy/breastfeeding Hypersensitivity to sodium iodide or ICG History of axillary surgery

Design outcomes

Primary

Measure	Time frame
Detection rate of ICG-labeled axillary SLN after NACT	—

Secondary

Measure	Time frame
SLN detection rate in the TAD setting when combined with ICG/radar markers Comparison of Detection Rates and Number of SLNs removed with ICG and Tc-99m Labeling	—

Countries

Germany

Contacts

Public ContactSteffi Hartmann

Universitätsfrauenklinik am Klinikum Südstadt

steffi.hartmann@kliniksued-rostock.de038144014500

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 29, 2026